CPD webinar · Respiratory / COPD · ~58 min · Otter transcript

COPD management strategies: act on the first exacerbation — single-inhaler triple therapy, rehab, vaccines and a smaller carbon footprint

A UK respiratory physician argues that COPD care has been too reactive: diagnose earlier, treat every exacerbation as a warning, escalate promptly to single-inhaler triple therapy when eligible, and don’t forget smoking cessation, pulmonary rehab, vaccines and cardiovascular risk — because a well-controlled patient is also a “green” patient.

Theme: glacier · Recorded 11 March 2026 (AEST) · Canonical: allcpd.drkotha.com/copd-management-strategies

Speaker: UK respiratory physician — introduced by the host as “Professor Cooks” and later addressed as “Mark” / “Mike” (name unclear on ASR). Works in the UK about an hour from Leeds, runs a COPD clinic with an embedded stop-smoking advisor, and describes research on COPD case-finding alongside lung cancer screening.
Host: Webinar moderator (name not captured) running Q&A from people dialled in at home and at Australian dinner-meeting sites.
Session context: Otter title COPD Management Strategies · id D2f_LQLbpPTHT2gWD76uYHeY4Bg · ~58 min, recorded 11 March 2026. Talk title as spoken: “sustainable solutions in COPD”. Speakers labelled Unknown Speaker / Speaker 1–4 (Speaker 1 and 4 are the same presenter). Sponsor: none named on the transcript; the evidence discussed centres on one company’s single-inhaler triple product (budesonide/glycopyrronium/formoterol — ASR “breast tree”, i.e. Breztri), so treat product comparisons with appropriate caution.

Already on allcpd: Asthma and COPD in general practice (Trelegy and triple therapy) and COPD biologics (the eosinophilic exacerbator). This post focuses on this speaker’s themes: the cost of each exacerbation, prompt escalation, and the environmental angle.

Key messages for GPs

Diagnose earlier. More than two-thirds of people had COPD-type events in their records in the five years before diagnosis — often “chest infections” and exacerbations.
One exacerbation is one too many. Exacerbations cause irreversible lung-function loss, predict the next exacerbation, raise cardiovascular risk and carry high mortality: about half of people die within four years of their first hospitalised exacerbation (Canadian data quoted).
Escalate promptly. Delay in stepping up to single-inhaler triple therapy, once eligible, was associated with more exacerbations and cardiopulmonary events.
Blood eosinophils ≥300 cells/µL predict benefit from an inhaled corticosteroid; GOLD 2026 suggests considering initial triple therapy in exacerbating patients at that level.
Non-drug care is equally important: smoking cessation at every visit, pulmonary rehab (and repeat it), vaccinations.
Treat cardiovascular risk — with moderate COPD you are more likely to die of cardiovascular disease than of COPD. Cardioselective beta-blockers should not be avoided.

Key takeaway

The speaker’s reframe: every exacerbation — and every healthcare contact — is an opportunity to prevent the next one. Review the diagnosis, inhaler choice and technique, smoking, rehab, vaccines and cardiovascular risk each time. Better control helps the patient, the health system and the environment at once.

The burden — and the hidden COPD

Just under 400 million people worldwide are diagnosed with COPD, but he called that “the tip of the iceberg”: many more live with symptoms and no diagnosis — and without a diagnosis they cannot access evidence-based treatment. In the UK, COPD is the second most common cause of unscheduled hospital admission, with winter pressure (“ambulances queued down the road”) driven partly by exacerbations.

Lung cancer screening finds hidden COPD. In a Leeds screening study, half of the people found to have airflow limitation already had a high symptom burden. In European screening data, those with newly found airflow limitation were already less physically active.
Missed opportunities in primary care. English primary-care records showed more than two-thirds of people had features consistent with COPD in the five years before diagnosis, many of them exacerbations.
Patients minimise symptoms. Asked “are you breathless?” many say no — until you ask what they can and cannot do. A cough is “just a smoker’s cough”. Clinicians, he admitted, can be guilty of the same.

Not just a spiral: the connected picture

The familiar “spiral of decline” — breathlessness → less activity → deconditioning → more breathlessness — is useful but feels nihilistic. He prefers a connected “diamond”: symptoms, exacerbations, cardiovascular events and death all influence each other.

Redrawn from the speaker’s description. More breathlessness and chronic productive cough predict exacerbations; exacerbations raise cardiovascular risk (dramatically after severe ones); both contribute to death.

Why every exacerbation matters

Lung function. In the WISDOM trial data he showed, FEV₁ started falling a few weeks before an exacerbation was recognised and, on average, did not recover to baseline — an irreversible loss. Frequent exacerbators decline faster.
Fear and isolation. In a UK qualitative study across four cities, patients drew their exacerbations: a man with elastic bands around his chest; a young woman who felt “haggard” and much older; a woman under a cloud who felt unseen. Breathlessness is a hidden symptom that shrinks people’s world — and patients often feel unprepared.
The next exacerbation comes sooner. After each severe exacerbation, the time to the next one shortens (Canadian cohort data).
Mortality. Half of people hospitalised for the first time with an exacerbation were dead within about four years — worse than many cancers, and under-recognised by clinicians.
Moderate exacerbations count too — those treated in the community with antibiotics or steroids also carry raised COPD and cardiovascular mortality.

Schematic only (not trial data). The speaker’s point: lung function drops before and during an exacerbation and on average does not fully return — preventing exacerbations helps prevent progression.

COPD and the environment

Every healthcare contact has a carbon cost, and the biggest costs come from high-intensity care: hospital admissions, ED visits and ambulance trips. A UK study he cited found people with no exacerbations had much lower healthcare-related greenhouse-gas emissions than frequent and severe exacerbators.

Pressurised metered-dose inhalers (pMDIs) are singled out in NHS emissions data because their propellants have been potent greenhouse gases — about 3–4% of total NHS emissions from one class of medicine (alongside anaesthetic gases). Propellants are changing.
But choice must be patient-centred. Many people need an MDI and it is the right device for them. The bigger win is control: uncontrolled disease drives emissions, which drive climate change, which worsens disease control — a vicious cycle.
His phrase: “a well-controlled patient… is a green patient.”

Based on the speaker’s slide narrative. Inhaler device choice still depends on the individual patient’s ability, preference and outcomes.

GOLD 2026: a more proactive approach

Respiratory medicine, he said, has been reactive — wait for an event, treat it, wait for the next. Cardiology focuses on risk and prevention, and COPD guidance is now moving that way.

GOLD groups people as A, B and E (the old C and D merged into E because exacerbations are what matter).
For group E, dual long-acting bronchodilator therapy (LABA/LAMA) may still be appropriate, but GOLD now advocates considering initial triple therapy when blood eosinophils are ≥300 cells/µL, recognising eosinophils as a treatable trait that predicts response to inhaled corticosteroids.
In many countries (including the UK) triple therapy is licensed only as a step up from dual therapy. In Australia, check current TGA indications and PBS restrictions.
He also highlighted Canadian guidance that explicitly uses risk language and the mortality data for triple therapy.

Triple-therapy evidence in brief

He focused on single-inhaler triple therapy (ICS/LAMA/LABA in one device), noting observational and some randomised data that it does better than the same drugs in multiple inhalers — possibly through adherence, simpler technique and drugs delivered together.

Trial (as named)	Design point he emphasised	Finding he reported
ETHOS	Large; primary endpoint moderate/severe exacerbations; patients needed a prior exacerbation	Fewer exacerbations vs LAMA/LABA (NNT ≈ 3 per year, as stated) and vs ICS/LABA (NNT figure garbled); mortality a key secondary endpoint — fed GOLD’s mortality statement
KRONOS	Primary endpoint lung function; no prior exacerbation required (~70% had none)	Exacerbations still reduced vs LAMA/LABA (NNT ≈ 3, as stated)
Other trials mentioned	IMPACT, TRIBUTE and others (names partly garbled)	Cited as the broader triple-therapy evidence base
Safety	ICS-containing arms	Small increase in pneumonia, outweighed in his view by exacerbation reduction; major adverse cardiovascular events appeared lower; mortality reduction appeared driven largely by cardiovascular deaths

Schematic of the pattern the speaker described from the ETHOS and KRONOS supplements: on an ICS-containing inhaler, exacerbation risk stays fairly flat across eosinophil levels; without ICS it rises as eosinophils rise. Not actual trial curves.

The treatment gap in real life

UK primary care (last 5–10 years): about one in five people with diagnosed COPD and no exacerbations were on no maintenance treatment — and a proportion (captured as “5%”, figure uncertain) of those with three moderate exacerbations, or a hospitalisation, were still on none. Only a minority of exacerbators were on guideline-recommended therapy.
US claims data: among people who became eligible for single-inhaler triple therapy (e.g. after a second moderate or a severe exacerbation), the smallest group started promptly (within 30 days). Delayed (31–180 days) and very delayed escalation were associated with higher exacerbation rates and, in a second cohort, more cardiopulmonary events.
Canada: a population case-finding trial randomised newly diagnosed people to a letter to the GP (usual care) or specialist care with respiratory educators; the intervention group was more often on optimal treatment and used less healthcare. Integrated community care for COPD reduced COPD admissions and also cardiovascular events.

Smoking, rehab and vaccines

Practical GP actions

Smoking: ask and offer support at every contact (behavioural support plus pharmacotherapy). In his clinic everyone — current or ex-smoker — sees a stop-smoking advisor before seeing him; “the one time you don’t mention smoking, the patient may take that as an endorsement.”
Pulmonary rehab: cost-effective; reduces symptoms and exacerbations, improves exercise capacity and quality of life, and affects mortality. It is not a once-only deal — benefits wear off over ~6–12 months, so re-refer.
Vaccines: about half of exacerbations are viral; influenza, COVID-19 and RSV vaccination reduce risk. (Cost of RSV vaccine in Australia was raised; he deferred to local context.)

Pulmonary rehab, he explained, is usually a 6–12-week programme (often twice weekly in six-week programmes) that combines tailored, progressive exercise with education, breathlessness management and chest clearance. Some UK services offer maintenance programmes. Patients often hear “exercise” and fear breathlessness, so explain that it is much more than a gym class.

Q&A highlights

Why is diagnosis delayed, and does lung screening help?

Patients minimise and normalise symptoms; clinicians attribute them to smoking or treat “chest infections” without doing spirometry. In his case-finding work, about a quarter had been treated for a chest infection in the year before diagnosis.
Lung cancer screening CT shows emphysema, which overlaps with (but isn’t the same as) COPD. In ~1,200 screened people at high risk, over half were diagnosed with COPD. As he quoted: mild emphysema on CT → ~50% have airflow limitation on spirometry; moderate–severe emphysema → ~80%. (Australia’s National Lung Cancer Screening Program was raised by the questioner.)
Anyone over about 35–40 with a smoking history and breathlessness, cough, sputum or recurrent chest infections should have COPD as a key differential → spirometry.

Echo, BNP and cardiovascular risk

Not everyone needs an echo. If heart failure is a differential, a BNP is a good discriminator — normal is reassuring; raised → echo.
COPD is itself a cardiovascular risk factor (the UK QRISK tool now includes it). Check BP, diabetes and lipids and treat per evidence — respiratory clinics, he admitted, often focus on saturations and miss this.
Do not avoid cardioselective beta-blockers in COPD when there is a cardiovascular indication.

Spirometry quality and imaging

Quality spirometry needs trained staff and funding; online training exists, and AI-supported reporting tools are emerging (one named on ASR as “Arctic” — possibly ArtiQ). He deferred to Australian speakers on local training pathways.
CT is not needed for everyone; do a chest X-ray. Proceed to CT if the X-ray is abnormal or there is clinical suspicion of something else — e.g. fine inspiratory crackles or clubbing suggesting interstitial lung disease.

Two pMDI triple therapies in Australia

Asked to compare the two pMDI single-inhaler triples available in Australia (ASR “Breztri” and, apparently, “Trimbow”), he said there are no head-to-head trials, so comparisons are indirect. He pointed to the larger evidence programme and ETHOS mortality data for budesonide/glycopyrronium/formoterol, and to MRI lung-deposition studies that appeared to favour it — while acknowledging nothing definitive. Note the possible sponsor context above.

Step down from triple therapy if stable?

When not to step down — and red flags

Generally no. Patients are stable because of the triple therapy, and ICS-withdrawal periods in trials showed more exacerbations. Exceptions: triple therapy was never appropriate, or recurrent pneumonia is a concern — a small minority.
Refer or escalate urgently: any hospitalised exacerbation (high 4-year mortality — review within weeks); two or more moderate exacerbations a year despite treatment; suspected heart failure (raised BNP) or interstitial lung disease (crackles, clubbing, abnormal X-ray); diagnostic uncertainty or poor-quality spirometry.

GP clinic checklist

Over ~35–40, smoking history, breathlessness/cough/sputum or repeat “chest infections” → spirometry (post-bronchodilator) to confirm or exclude COPD.
Ask about function, not just “are you breathless?” — record an MRC/mMRC breathlessness score.
Code and count exacerbations, including moderate ones treated with antibiotics/steroids; treat each as a trigger to review treatment.
Check blood eosinophils; with exacerbations and eosinophils ≥300 cells/µL consider single-inhaler triple therapy (per PBS criteria) — escalate promptly, not months later.
Check inhaler technique and device suitability; prefer one device over several where possible; discuss lower-carbon options only when they suit the patient.
Don’t step down stable patients from triple therapy without a clear reason.
Smoking cessation support at every visit; refer (and re-refer) to pulmonary rehab; offer influenza, COVID-19, RSV (and other recommended) vaccines.
Assess cardiovascular risk; manage BP, lipids and glucose; use cardioselective beta-blockers when indicated; BNP before echo if heart failure is a question.
After any hospital admission for COPD, review early and give a written action plan.

allcpd.drkotha.com · directory